Loading
Low-grade serous ovarian cancer is a slow-growing, RAS-driven type of ovarian cancer that resists chemotherapy but responds to hormone blockers and MEK-pathway drugs.
About 5-10% of serous ovarian cancers; younger patients, KRAS/BRAF/NRAS mutations in ~30-50%, wild-type TP53, strong ER expression, low proliferation. Chemotherapy response rates are under 25%; endocrine therapy and MEK/RAF pathway inhibition (trametinib in GOG 281; avutometinib + defactinib, approved 2025) are the mainstays. Contrast with high-grade serous carcinoma.
In plain words · KRAS is the most commonly mutated cancer gene, called 'undruggable' for 40 years until 2021.
Showing the target this term concerns: KRAS.
Shares Avutometinib + defactinib, Invasion: proteases, adhesion & the invasive front, KRAS, Ovarian cancer.
Shares RAMP 201, Avutometinib + defactinib, RAS / RAF / MEK / ERK (MAPK), KRAS.
Shares Letrozole (and other aromatase inhibitors), Ovarian cancer.
Shares Letrozole (and other aromatase inhibitors), Ovarian cancer.
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
Shares Letrozole (and other aromatase inhibitors), Ovarian cancer.
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.
Shares RAS / RAF / MEK / ERK (MAPK), KRAS.